Osimertinib
Chemical compound, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, used as a medication to treat non-small-cell lung carcinomas with a specific mutation
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Nº Q21506464 ★
Common · Knowledge
Osimertinib
Chemical compound, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, used as a medication to treat non-small-cell lung carcinomas with a specific mutation
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue, and cough. Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.
Text: Wikipédia, CC BY-SA 4.0. · Image: Vaccinationist (Public domain) ·
